ESPERION THERAPEUTICS INC. - COMMON STOCK

Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC

19 Apr 2023 05:42:01 By Nasdaq GlobeNewswire

Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference

03 Apr 2023 05:00:00 By Nasdaq GlobeNewswire

Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

22 Mar 2023 13:15:00 By Nasdaq GlobeNewswire

Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

20 Mar 2023 05:00:00 By Nasdaq GlobeNewswire

International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk

08 Mar 2023 05:00:00 By Nasdaq GlobeNewswire

Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients

04 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Esperion Launches New Scientific Website

24 Feb 2023 10:40:00 By Nasdaq GlobeNewswire

Esperion to Participate in the Cowen 43rd Annual Healthcare Conference

23 Feb 2023 05:00:02 By Nasdaq GlobeNewswire

CLEAR Outcomes Company Update Call: Detailed Results Discussion

22 Feb 2023 05:00:01 By Nasdaq GlobeNewswire

Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

21 Feb 2023 04:00:01 By Nasdaq GlobeNewswire

Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC

20 Feb 2023 05:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

13 Feb 2023 13:30:00 By Nasdaq GlobeNewswire

Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023

07 Feb 2023 05:00:01 By Nasdaq GlobeNewswire

RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500

11 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results

08 Jan 2023 16:00:00 By Nasdaq GlobeNewswire

CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)

19 Dec 2022 13:15:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

13 Dec 2022 15:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in January Investor Meetings

13 Dec 2022 05:00:01 By Nasdaq GlobeNewswire

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

07 Dec 2022 05:05:00 By Nasdaq GlobeNewswire

Esperion Appoints Ben Halladay Chief Financial Officer

16 Nov 2022 13:00:00 By Nasdaq GlobeNewswire